Posted by Michael Wonder on 01 Nov 2020
Novartis sickle cell medicine Adakveo approved in Europe to prevent recurrent vaso-occlusive crises
30 October 2020 - Adakveo is the first targeted sickle cell disease therapy for prevention of recurrent vaso-occlusive crises available for use in Europe.
Novartis today announced that the European Commission has approved Adakveo (crizanlizumab) for the prevention of recurrent vaso-occlusive crises, or pain crises, in patients with sickle cell disease aged 16 years and older.
Adakveo can be given as an add-on therapy to hydroxyurea or as monotherapy in patients for whom hydroxyurea is inappropriate or inadequate.
